BioSpace News Archive

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2021 and provided an operational update.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced financial results for the second quarter ended June 30, 2021.

BIOLASE, Inc., the global leader in dental lasers, announced its financial results for its second quarter ended June 30, 2021 and provided third quarter 2021 revenue guidance.

Cytocom, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology, a not-for-profit academic institution and a world leader in immunology research.

ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported financial and operating results for the second quarter ended June 30, 2021 and provided a corporate strategic update.

NovaBay® Pharmaceuticals, Inc. reports financial results for the three and six months ended June 30, 2021 and provides a business update.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2021 to all shareholders of record as of September 15, 2021.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced its second quarter 2021 financial results and corporate highlights.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2021.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.